8
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Two regimens of vaginal misoprostol in second trimester termination of pregnancy – a prospective randomised trial

, , , &
Pages 1458-1462 | Received 21 Mar 2006, Published online: 03 Aug 2009
 

Abstract

Background. The search continues for a safe, effective, and cheap method for mid-trimester termination of pregnancy. Misoprostol is a strong contender in this respect. The dose schedule of misoprostol is still not fixed. The objective of our present study was to compare the efficacy and adverse events of 2 dose regimens of vaginal misoprostol for second trimester termination. Method. A prospective, randomised, controlled trial was undertaken in 138 women at 14–20 weeks gestation, in a teaching hospital. Subjects were randomised to receive either regime A: 400 µg of intravaginal misoprostol every 3 h, or regime B: loading dose of 600 µg, followed by 200 µg every 3 h. The main outcome measure was the success rate at 48 h, total dose required, induction-abortion interval, and adverse events. Data was analysed by Student's t-test, Mann–Whitney U-test, the chi-squared test or Fisher's exact test, using Statistica 6.0 software. Results. There was no significant difference in the success rates at 24 and 48 h (Regime A: 97.18 and 98.59%; Regime B: 95.45 and 95.45%), and in mean induction-abortion interval (12.97 versus 12.13 h). However, mean misoprostol requirement was significantly higher for Regime A (1701.4 versus 1269.7 µg). The incidence of fever was significantly less in Regime B (32.4 versus 14.9%). Conclusion. Use of vaginal misoprostol for second trimester abortion had comparable efficacy with less drug requirement for the 600 µg loading dose followed by 200 µg 3-hourly regime compared to the 400 µg 3-hourly regime.

Acronyms
Po=

parity zero

P1=

parity one

S=

significant

NS=

not significant

HS=

highly significant

Acronyms
Po=

parity zero

P1=

parity one

S=

significant

NS=

not significant

HS=

highly significant

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.